Archimedis Laboratories Profile
Key Indicators
- Authorised Capital ₹ 9.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 7.01 Cr
as on 24-10-2024
- Company Age 19 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 63.75 Cr
as on 24-10-2024
- Satisfied Charges ₹ 16.04 Cr
as on 24-10-2024
- Revenue -3.42%
(FY 2023)
- Profit -41.49%
(FY 2023)
- Ebitda -16.13%
(FY 2023)
- Net Worth 5.43%
(FY 2023)
- Total Assets 68.97%
(FY 2023)
About Archimedis Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.00 Cr and a paid-up capital of Rs 7.01 Cr.
The company currently has active open charges totaling ₹63.75 Cr. The company has closed loans amounting to ₹16.04 Cr, as per Ministry of Corporate Affairs (MCA) records.
Venkateswara Maddireddy and Kesava Maddireddy serve as directors at the Company.
- CIN/LLPIN
U24239TG2004PTC044970
- Company No.
044970
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Dec 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Archimedis Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkateswara Maddireddy  | Director | 24-Dec-2004 | Current |
| Kesava Maddireddy | Director | 24-Dec-2004 | Current |
Financial Performance of Archimedis Laboratories.
Archimedis Laboratories Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.42% decrease. The company also saw a substantial fall in profitability, with a 41.49% decrease in profit. The company's net worth moved up by a moderate rise of 5.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Archimedis Laboratories?
In 2023, Archimedis Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 27 Apr 2022 | ₹50.75 Cr | Open |
Axis Bank Limited Creation Date: 31 Jan 2017 | ₹13.00 Cr | Open |
Andhra Bank Creation Date: 01 Nov 2010 | ₹9.61 Cr | Satisfied |
How Many Employees Work at Archimedis Laboratories?
Archimedis Laboratories has a workforce of 87 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Archimedis Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Archimedis Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
